The CARI guidelines. Evidence for peritonitis treatment and prophylaxis: indications for the use of urokinase in peritoneal dialysis-associated peritonitis.
D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D014568:Urokinase-Type Plasminogen Activator